Revolutionizing Endometrial Cancer Treatment: Ideaya’s IDE161 and Keytruda Join Forces in Groundbreaking Phase 1 Clinical Trial
First patient dosed with IDE161 and KEYTRUDA® Combination in Endometrial Cancer Trial IDEAYA Biosciences Announces Groundbreaking Phase 1 Clinical Trial SOUTH SAN FRANCISCO, Calif., Dec. 10, 2024 /PRNewswire/ — IDEAYA Biosciences, a leading precision medicine oncology company, has marked a significant milestone by dosing the first patient in a Phase 1 clinical trial to evaluate…